Medical technology using machine learning to analyze the immune system’s response

Memed is a medical technology company that uses machine learning to analyse the immune system’s response and assist in the diagnosis of infections. It’s primary goal is to improve diagnosis and treatment decision for various medical conditions. The company has developed a host immune response technology and is focused on providing physicians with tools to improve patient management. MeMed BV® is the first FDA-cleared host-immune response assay for accurately distinguishing between bacterial and viral infections in just 15 minutes; MeMed Key® is a cutting edge, compact immunoassay platform that makes it possible to conduct highly sensitive, quick, multiplexed protein measurements that previously could only be done on large, expensive central lab equipment.

Funds

La Maison ITF 2

Company

MeMed

Investment date

2021

Strategy

Venture capital

Status

Active

Sector

Health

World region

Israel